Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Doravirine/Islatravir versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Patients
jRCT2080225071Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of doravirine + islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of participants with HIV-1 RNA ≥50 copies/mL at Week 48 (FDA Snapshot). Started Feb 2020; status: completed.
02
Drugs
doravirine + islatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2080225071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225071.